Literature DB >> 10344760

Overexpression of cyclins D1 and E is frequent in bronchial preneoplasia and precedes squamous cell carcinoma development.

F Lonardo1, V Rusch, J Langenfeld, E Dmitrovsky, D S Klimstra.   

Abstract

Increased protein expression of the G1 cyclins D1 and E is reported in invasive non-small cell lung carcinoma. However, during transformation of the bronchial epithelium, overexpression of these species occurs, and their relationship to aberrant expression of p53 and retinoblastoma (Rb) has not been described previously. To determine the expression of these cell cycle regulators during the development of invasive squamous cell carcinoma (SCC) of the lung, the immunohistochemical expression patterns in normal bronchial epithelium (n = 36), squamous metaplasia (SM; n = 28), and epithelial atypia (n = 34) were compared with that in low-grade dysplasia (LGD; n = 17), high-grade bronchial dysplasia (HGD; n = 30), and SCC (n = 36). Monoclonal anti-p53 Pab1801, polyclonal anti-cyclin D1 DCS6, monoclonal anti-cyclin E HE12, and monoclonal anti-Rb OP-66 antibodies were used. Cyclin D1 was not expressed in normal bronchial epithelium but was detected in 7% of SMs, 15% of atypias; 18% of LGDs, 47% of HGDs, and 42% of SCCs. Cyclin E was not detected in normal epithelium (n = 24), SM (n = 16), or LGD (n = 12), but it was found in 9% of atypias (2 of 22), 33% of HGDs (7 of 21), and 54% of SCCs (13 of 24). p53 was not expressed in normal epithelium, SM, and LGD, but it was overexpressed in 6% of atypias, 53% of HGDs, and 61% of SCCs. Abnormal Rb expression was found only in 2 of 36 cases of SCC. A total of 91% of HGDs and 92% of SCCs exhibited overexpression of at least one of the p53, cyclin D1, or cyclin E species. However, no link was observed between overexpression of p53 and the overexpressed G1 cyclins in preneoplastic lesions. Overexpression of cyclin D1, cyclin E, and p53 occurs frequently and independently in pulmonary SCC and is detected in lesions before the development of invasive carcinoma. In contrast, altered Rb expression is a late and infrequent event in squamous cell carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10344760

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  30 in total

1.  Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models.

Authors:  Konstantin H Dragnev; Tian Ma; Jobin Cyrus; Fabrizio Galimberti; Vincent Memoli; Alexander M Busch; Gregory J Tsongalis; Marc Seltzer; David Johnstone; Cherie P Erkmen; William Nugent; James R Rigas; Xi Liu; Sarah J Freemantle; Jonathan M Kurie; Samuel Waxman; Ethan Dmitrovsky
Journal:  Cancer Prev Res (Phila)       Date:  2011-06

2.  Anaphase catastrophe is a target for cancer therapy.

Authors:  Fabrizio Galimberti; Sarah L Thompson; Saranya Ravi; Duane A Compton; Ethan Dmitrovsky
Journal:  Clin Cancer Res       Date:  2011-02-02       Impact factor: 12.531

3.  Targeting the cyclin E-Cdk-2 complex represses lung cancer growth by triggering anaphase catastrophe.

Authors:  Fabrizio Galimberti; Sarah L Thompson; Xi Liu; Hua Li; Vincent Memoli; Simon R Green; James DiRenzo; Patricia Greninger; Sreenath V Sharma; Jeff Settleman; Duane A Compton; Ethan Dmitrovsky
Journal:  Clin Cancer Res       Date:  2009-12-22       Impact factor: 12.531

Review 4.  Lung cancer. 1: prevention of lung cancer.

Authors:  G E Goodman
Journal:  Thorax       Date:  2002-11       Impact factor: 9.139

Review 5.  Cancer and autoimmunity: autoimmune and rheumatic features in patients with malignancies.

Authors:  M Abu-Shakra; D Buskila; M Ehrenfeld; K Conrad; Y Shoenfeld
Journal:  Ann Rheum Dis       Date:  2001-05       Impact factor: 19.103

6.  Thyroid hormone and the d-type cyclins interact in regulating enterocyte gene transcription.

Authors:  S Meng; J Badrinarain; E Sibley; R Fang; R Hodin
Journal:  J Gastrointest Surg       Date:  2001 Jan-Feb       Impact factor: 3.452

7.  CBX7 is a tumor suppressor in mice and humans.

Authors:  Floriana Forzati; Antonella Federico; Pierlorenzo Pallante; Adele Abbate; Francesco Esposito; Umberto Malapelle; Romina Sepe; Giuseppe Palma; Giancarlo Troncone; Marzia Scarfò; Claudio Arra; Monica Fedele; Alfredo Fusco
Journal:  J Clin Invest       Date:  2012-01-03       Impact factor: 14.808

8.  The CDK4/6 inhibitor PD0332991 reverses epithelial dysplasia associated with abnormal activation of the cyclin-CDK-Rb pathway.

Authors:  M Carla Cabrera; Edgar S Díaz-Cruz; Bhaskar V S Kallakury; Michael J Pishvaian; Clinton J Grubbs; Donald D Muccio; Priscilla A Furth
Journal:  Cancer Prev Res (Phila)       Date:  2012-04-16

9.  UBE1L causes lung cancer growth suppression by targeting cyclin D1.

Authors:  Qing Feng; David Sekula; Yongli Guo; Xi Liu; Candice C Black; Fabrizio Galimberti; Sumit J Shah; Lorenzo F Sempere; Vincent Memoli; Jesper B Andersen; Bret A Hassel; Konstantin Dragnev; Ethan Dmitrovsky
Journal:  Mol Cancer Ther       Date:  2008-12       Impact factor: 6.261

10.  Comparing histone deacetylase inhibitor responses in genetically engineered mouse lung cancer models and a window of opportunity trial in patients with lung cancer.

Authors:  Tian Ma; Fabrizio Galimberti; Cherie P Erkmen; Vincent Memoli; Fadzai Chinyengetere; Lorenzo Sempere; Jan H Beumer; Bean N Anyang; William Nugent; David Johnstone; Gregory J Tsongalis; Jonathan M Kurie; Hua Li; James Direnzo; Yongli Guo; Sarah J Freemantle; Konstantin H Dragnev; Ethan Dmitrovsky
Journal:  Mol Cancer Ther       Date:  2013-05-16       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.